A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients

被引:93
作者
Alsner, Jan [1 ]
Jensen, Vibeke [2 ]
Kyndi, Marianne [1 ]
Offersen, Birgitte Vrou [1 ]
Vu, Phuong [3 ]
Borresen-Dale, Anne-Lise [3 ,4 ]
Overgaard, Jens [1 ]
机构
[1] Aarhus Univ Hosp, Dept Expt Clin Oncol, DK-8000 Aarhus C, Denmark
[2] Aarhus Univ Hosp, Inst Pathol, Aalborg, Denmark
[3] Rikshosp Univ Hosp, Norwegian Radium Hosp, Inst Canc Res, Dept Genet, N-0027 Oslo, Norway
[4] Univ Oslo, Norwegian Radium Hosp, Fac Div, Oslo, Norway
关键词
D O I
10.1080/02841860802047411
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Background. p53 accumulation and TP53 mutations are known prognostic markers for breast cancer. To clarify their interrelationship and the importance of different TP53 mutation types, these markers were investigated in tumours; from 630 patients with breast cancer. Materials and methods. Tumour sections were stained for p53 and scored based on staining intensity and percentages of invasive tumour cells with nuclear staining. TP53 mutations were identified by sequencing. Patient cohorts were from the DBCG (Danish Breast Cancer Cooperative Group) protocols DBCG82 and DBCG89. Results. TP53 was mutated in 29% of the patients. The disease-specific survival (DSS) at 15 years of follow-up for patients with missense mutations directly involved in DNA or zinc binding was 21 +/- 8%. Patients with the remaining missense mutations within the structural/conserved domains and patients with null mutations had a DSS of 36+/-6% and 31+/-17%, respectively. For patients without TP53 mutations and patients with mutations affecting amino acids outside these domains, the 15 year DSS was 51+/-3% and 71+/-10%, respectively. p53 accumulation was successfully scored in 567 patients and categorized into three groups. Tumours with no p53 expression had a high frequency of null mutations (37% compared to 10% in the whole cohort), and tumours with high p53 expression contained 82% of the missense mutations inside structural/conserved domains including those directly involved in DNA or zinc binding. Conclusion. The clinical outcome for breast cancer patients is significantly different for different TP53 mutation types, but further functional studies are required to clarify the exact role of these mutation types. Most of the mutations that lead to mutant p53 protein accumulation can be detected by immunohistochemistry but the specificity is low. Samples showing lack of detectable p53 protein should be considered as an indication of a possible null mutation.
引用
收藏
页码:600 / 607
页数:8
相关论文
共 18 条
[1]
Alsner J, 2000, CLIN CANCER RES, V6, P3923
[2]
P53 IMMUNOHISTOCHEMISTRY - A WORD OF CAUTION [J].
BATTIFORA, H .
HUMAN PATHOLOGY, 1994, 25 (05) :435-437
[3]
PROBLEMS WITH P53 IMMUNOHISTOCHEMICAL STAINING - THE EFFECT OF FIXATION AND VARIATION IN THE METHODS OF EVALUATION [J].
FISHER, CJ ;
GILLETT, CE ;
VOJTESEK, B ;
BARNES, DM ;
MILLIS, RR .
BRITISH JOURNAL OF CANCER, 1994, 69 (01) :26-31
[4]
Molecular genetic analysis of easily accessible breast tumour DNA, purified from tissue left over from hormone receptor measurement [J].
Hansen, LL ;
Andersen, J ;
Overgaard, J ;
Kruse, TA .
APMIS, 1998, 106 (03) :371-377
[5]
Tissue microarrays compared with whole sections and biochemical analyses. A subgroup analysis of DBCG82 b&c [J].
Kyndi, M. ;
Sorensen, F. B. ;
Knudsen, H. ;
Overgaard, M. ;
Nielsen, H. M. ;
Andersen, J. ;
Overgaard, J. .
ACTA ONCOLOGICA, 2008, 47 (04) :591-599
[6]
Impact of BCL2 and p53 on postmastectomy radiotherapy response in high-risk breast cancer. A subgroup analysis of DBCG82 b&c [J].
Kyndi, M. ;
Sorensen, F. B. ;
Knudsen, H. ;
Alsner, J. ;
Overgaard, M. ;
Nielsen, H. M. ;
Overgaard, J. .
ACTA ONCOLOGICA, 2008, 47 (04) :608-617
[7]
Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: Long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies [J].
Nielsen, HM ;
Overgaard, M ;
Grau, C ;
Jensen, AR ;
Overgaard, J .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (15) :2268-2275
[8]
A comparison among HER2, TP53, PAI-1, angiogenesis, and proliferation activity as prognostic variables in tumours from 408 patients diagnosed with early breast cancer [J].
Offersen, Birgitte Vrou ;
Alsner, Jan ;
Olsen, Karen Ege ;
Riisbro, Rikke ;
Bruenner, Nils ;
Sorensen, Flemming Brandt ;
Sorensen, Boe Sandahl ;
Schlemmer, Birgitte Olrik ;
Overgaard, Jens .
ACTA ONCOLOGICA, 2008, 47 (04) :618-632
[9]
Chalkley estimates of angiogenesis in early breast cancer - Relevance to prognosis [J].
Offersen, BV ;
Sorensen, FB ;
Yilmaz, M ;
Knoop, A ;
Overgaard, J .
ACTA ONCOLOGICA, 2002, 41 (7-8) :695-703
[10]
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer [J].
Olivier, M ;
Langerod, A ;
Carrieri, P ;
Bergh, J ;
Klaar, S ;
Eyfjord, J ;
Theillet, C ;
Rodriguez, C ;
Lidereau, R ;
Bièche, I ;
Varley, J ;
Bignon, Y ;
Uhrhammer, N ;
Winqvist, R ;
Jukkola-Vuorinen, A ;
Niederacher, D ;
Kato, S ;
Ishioka, C ;
Hainaut, P ;
Borresen-Dale, AL .
CLINICAL CANCER RESEARCH, 2006, 12 (04) :1157-1167